ArticleFrontiers in immunology2021
Evidence of SARS-CoV-2-Specific Memory B Cells Six Months After Vaccination With the BNT162b2 mRNA Vaccine.
Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
81 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Characterization of the significant decline in humoral immune response six months post-SARS-CoV-2 mRNA vaccination: A systematic review.Journal of medical virology · 2022Pooled it
- Heterologous vector versus homologous mRNA COVID-19 booster vaccination in non-seroconverted immunosuppressed patients: a randomized controlled trial.Nature communications · 2022Trial
- Article
- Evaluating Memory B Cell Cross-Reactivity Between Ancestral and Future SARS-CoV-2 Variants-Evidence for Original Antigenic Sin.Vaccines · 2026Article
- Flow Cytometric Assessment of Pertactin- and Tetanus Toxoid-Specific B-Cell Kinetics After Tdap Booster Vaccination in Healthy Adults.Vaccines · 2026Article
- Class switching toward IgG4 six months after primary mRNA-based COVID-19 vaccination in kidney patients.PloS one · 2026Article
- T and B cell responses following primary COVID-19 vaccination with CoronaVac and two heterologous BNT162b2 booster doses.mSphere · 2025Article
- SARS-CoV-2-specific B cell responses in non-draining lymph nodes and antibody functionalities in immunized end-stage renal disease patients.Scientific reports · 2025Article
- Booster dose reshapes SARS-CoV-2 RBD-specific B cell immunity in people living with HIV.Journal of translational medicine · 2025Article
- Machine learning approaches to dissect hybrid and vaccine-induced immunity.Communications medicine · 2025Article
- Psychological booster shots targeting memory increase long-term resistance against misinformation.Nature communications · 2025Article
- T and B cell responses in different immunization scenarios for COVID-19: a narrative review.Frontiers in immunology · 2025Review
- A genome-wide association study identifies new loci associated with response to SARS-CoV-2 mRNA-1273 vaccine in a cohort of healthy healthcare workers.Frontiers in immunology · 2025Article
- Analysis of humoral and cellular immune activation up to 21 months after heterologous and homologous COVID-19 vaccination.Frontiers in immunology · 2025Article
- Dynamic SARS-CoV-2-specific B-cell and T-cell responses induced in people living with HIV after a full course of inactivated SARS-CoV-2 vaccine.Frontiers in immunology · 2025Article
- Review
- Vaccine responses and hybrid immunity in people living with HIV after SARS-CoV-2 breakthrough infections.NPJ vaccines · 2024Article
- AS03 adjuvant enhances the magnitude, persistence, and clonal breadth of memory B cell responses to a plant-based COVID-19 vaccine in humans.Science immunology · 2024Article
- Non-cross-reactive epitopes dominate the humoral immune response to COVID-19 vaccination - kinetics of plasma antibodies, plasmablasts and memory B cells.Frontiers in immunology · 2024Article
- Does Nirmatrelvir/Ritonavir Influence the Immune Response against SARS-CoV-2, Independently from Rebound?Microorganisms · 2023Article
21 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SARS-CoV-2 mRNA vaccines have demonstrated high efficacy and immunogenicity, but limited information is currently available on memory B cell generation and long-term persistence. Here, we investigated spike-specific memory B cells and humoral responses in 145 subjects, up to 6 months after the BNT162b2 vaccine (Comirnaty) administration. Spike-specific antibodies peaked 7 days after the second dose and significant antibody titers and ACE2/RBD binding inhibiting activity were still observed after 6 months, despite a progressive decline over time. Concomitant to antibody reduction, spike-specific memory B cells, mostly IgG class-switched, increased in the blood of vaccinees and persisted 6 months after vaccination. Following the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.